Last 48 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.39 | — | — | — | — | — | — | — | 3.81 | — | — | 1.97 | — | — | — | — | — | — | — | — | 1.73 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.43 | 1.98 | 27.66 | 113.68 | 10.00 | 33.66 | 6.79 | 45.30 | 1.89 | — | 122.91 | 0.91 | 17.15 | — | — | 128.75 | — | — | 35.84 | — | 1.37 |
| — | -94.1% | +307.5% | +150.9% | +428.0% | — | -94.5% | +4854.4% | -89.0% | — | — | -99.3% | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.62 | 0.86 | 0.97 | 2.38 | 3.17 | 1.09 | 0.99 | 0.89 | 1.26 | 1.26 | 2.08 | 1.16 | 0.73 | 0.70 | 0.92 | 0.89 | 0.99 | 1.07 | 1.80 | 2.85 | 1.93 |
| — | -21.4% | -2.1% | +168.5% | +151.2% | -13.1% | -52.4% | -23.8% | +73.1% | +79.1% | +124.7% | +31.2% | -26.8% | -34.2% | -48.6% | -68.9% | -48.6% | -63.9% | -48.4% | -2.2% | -67.3% | |
| P/FCF | — | 0.86 | — | — | — | — | — | — | 3.91 | — | — | 2.89 | — | — | — | — | — | — | — | — | 2.45 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | 3.24 | — | — | 1.92 | — | — | — | — | — | — | — | — | 1.71 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | 2.84 | — | — | 1.76 | — | — | — | — | — | — | — | — | 1.73 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -334.3% | — | 100.0% | 87.6% | 98.7% | 100.0% | -243.1% | 100.0% | 100.0% | — | -1993.1% | 100.0% | 100.0% | 100.0% | — | 100.0% | — | — | -479.6% | — | 86.0% |
| — | — | +141.1% | -12.4% | -1.3% | — | +87.8% | 0.0% | 0.0% | — | — | 0.0% | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -524.7% | — | -1495.1% | -3224.1% | -219.6% | -2933.5% | -386.0% | -2226.8% | 44.3% | — | -3676.2% | 42.3% | -1199.6% | 225.6% | — | -7889.9% | — | — | -705.5% | — | 79.5% |
| — | — | -287.3% | -44.8% | -596.2% | — | +89.5% | -5363.6% | +103.7% | — | — | +100.5% | — | — | — | — | — | — | — | — | — | |
| Net Margin | -487.1% | -29.1% | -1379.6% | -3075.4% | -206.9% | -2781.5% | -354.1% | -1986.8% | 51.0% | — | -3426.2% | 46.1% | -1055.7% | 213.0% | — | -7038.1% | — | — | -526.4% | — | 78.5% |
| — | +99.0% | -289.6% | -54.8% | -505.4% | — | +89.7% | -4407.1% | +104.8% | — | — | +100.7% | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -54.3% | -3.1% | -11.8% | -19.7% | -16.6% | -20.4% | -12.1% | -9.3% | 8.9% | -11.0% | -13.6% | 15.9% | -10.7% | -26.1% | -11.7% | -11.5% | -6.1% | -6.2% | -6.4% | -7.9% | 32.2% |
| — | +84.8% | +3.1% | -112.2% | -286.4% | -85.2% | +10.6% | -158.5% | +183.4% | +57.8% | -15.9% | +238.4% | -75.0% | -319.5% | -83.4% | -44.4% | -118.9% | +30.9% | +63.3% | +32.0% | +206.6% | |
| ROA | -48.7% | -2.8% | -10.7% | -17.3% | -14.3% | -18.4% | -11.3% | -8.7% | 8.2% | -10.1% | -12.7% | 14.5% | -9.6% | -24.1% | -11.0% | -10.8% | -5.8% | -5.9% | -5.9% | -7.0% | 27.2% |
| — | +84.6% | +5.6% | -99.9% | -273.7% | -81.3% | +10.8% | -159.8% | +186.3% | +57.9% | -15.1% | +234.1% | -65.0% | -307.9% | -87.7% | -55.2% | -121.3% | +16.1% | +57.9% | +21.4% | +251.0% | |
| ROIC | -63.5% | — | -12.3% | -21.0% | -18.8% | -23.5% | -13.4% | -10.2% | 7.7% | -12.7% | -13.5% | 13.3% | -11.4% | -25.1% | -11.7% | -10.9% | -5.7% | -6.2% | -7.2% | -5.7% | 25.1% |
| — | — | +8.0% | -104.9% | -344.1% | -84.6% | +0.9% | -177.2% | +167.5% | +49.3% | -15.6% | +221.5% | -100.8% | -304.9% | -61.5% | -92.9% | -122.6% | +29.2% | +1.8% | +59.4% | +134.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | — | — | — | 0.03 | 0.01 | — | — | — | — | — | — | — | 0.01 | — | — | — | — | — | 0.03 | 0.05 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -70.8% | -86.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.18 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.68 | 11.36 | 11.48 | 9.99 | 6.68 | 8.25 | 12.71 | 15.64 | 14.75 | 12.97 | 12.56 | 16.99 | 8.69 | 10.98 | 14.82 | 15.86 | 20.34 | 23.89 | 22.23 | 12.36 | 8.26 |
| — | +37.7% | -9.7% | -36.1% | -54.8% | -36.4% | +1.2% | -7.9% | +69.8% | +18.1% | -15.3% | +7.1% | -57.3% | -54.0% | -33.3% | +28.4% | +146.3% | +280.8% | +315.2% | +45.2% | +114.6% | |
| Quick Ratio | 6.68 | 11.36 | 11.48 | 9.99 | 6.68 | 8.25 | 12.71 | 15.64 | 14.75 | 12.97 | 12.56 | 16.99 | 8.69 | 10.98 | 14.82 | 15.86 | 20.34 | 23.89 | 22.23 | 12.36 | 8.26 |
| — | +37.7% | -9.7% | -36.1% | -54.8% | -36.4% | +1.2% | -7.9% | +69.8% | +18.1% | -15.3% | +7.1% | -57.3% | -54.0% | -33.3% | +28.4% | +146.3% | +280.8% | +315.2% | +45.2% | +114.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -346.75 | — | 394.87 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LPCN stock.
Lipocine Inc.'s current P/E is -1.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Lipocine Inc.'s current operating margin is -524.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Lipocine Inc.'s business trajectory between earnings reports.